Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. Read more >>